Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena plus a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change.
Phase of Trial: Phase IV
Latest Information Update: 11 May 2018
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders
- Focus Therapeutic Use
- Acronyms BD-CAEL
- 01 May 2018 Status changed from not yet recruiting to recruiting.
- 30 Jan 2018 New trial record